Zulfiya Zhankalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zulfiya Zhankalova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aigul Durmanova
Department of Internal Medicine, University Medical Center, 46 Syganak St., Astana 010000, Kazakhstan
1 shared publication - Akmaral Izbassarova
Department of Physical Medicine and Rehabilitation, Sports Medicine, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan
1 shared publication - Alisher Idrisov
Astana Medical University, Kazakhstan
1 shared publication - Almat Turysbekuly
Research Management Department, Research Institute of Cardiology and Internal Diseases, Almaty 050000, Kazakhstan
1 shared publication - Altay Nabiyev
Clinical Academic Department for Internal Medicine, University Medical Center, Syganak Str., 46, Astana 010000, Kazakhstan
1 shared publication - Anel Zhumabek
Research Management Department, Research Institute of Cardiology and Internal Diseases, Almaty 050000, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8908
Digital Cardiac Rehabilitation Following Coronary Revascularization: Effectiveness, Safety, Implementation Barriers and Future Development
Background/Objectives: To critically review the effectiveness, safety and implementation of fully remote, hybrid and digitally supported cardiac rehabilitation (CR) in adults after coronary revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), distinguishing direct from indirect evidence. Methods: This structured narrative review drew on searches of MEDLINE (PubMed), Embase, the Cochrane Library, Scopus and Web of Science, supplemented by reference list and citation searching and by guidance from major cardiology societies. Randomized and non-randomized comparative studies, economic evaluations, qualitative studies and systematic reviews were selected purposively, appraised qualitatively for methodological limitations, and synthesized narratively by outcome, comparator, intervention comprehensiveness and directness of evidence for revascularized patients. Results: Compared with usual care, digital CR improved short-term exercise capacity; compared with center-based CR, it produced broadly similar exercise capacity and short- to intermediate-term quality of life. Lower odds of all-cause readmission with digital CR in one meta-analysis (OR 0.37, 95% CI 0.25–0.56) were based on only seven heterogeneous studies (n = 859) and are not corroborated by the 2023 Cochrane review; effects on major adverse cardiovascular events and mortality remain uncertain. Economic evaluations were generally favorable. Serious exercise-related adverse events were rarely reported in the selected, predominantly lower-risk participants studied, but surveillance was inconsistent, and safety after CABG and in higher-risk patients has not been established. Reimbursement, workforce capacity, interoperability and digital exclusion were the main implementation barriers. Conclusions: Comprehensive remote or hybrid CR is a reasonable option for appropriately assessed, clinically stable, lower-risk patients, particularly after PCI, and a promising way to reach those who would otherwise receive no rehabilitation; patients in the early period after CABG or at higher risk should start with supervised center-based or hybrid care. Digital CR should widen access to multidisciplinary rehabilitation rather than replace supervised programs, and adequately powered trials with long-term clinical and standardized safety outcomes are needed.
- 13 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8908
Open AccessDigital Cardiac Rehabilitation Following Coronary Revascularization: Effectiveness, Safety, Implementation Barriers and Future Development
Background/Objectives: To critically review the effectiveness, safety and implementation of fully remote, hybrid and digitally supported cardiac rehabilitation (CR) in adults after coronary revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), distinguishing direct from indirect evidence. Methods: This structured narrative review drew on searches of MEDLINE (PubMed), Embase, the Cochrane Library, Scopus and Web of Science, supplemented by reference list and citation searching and by guidance from major cardiology societies. Randomized and non-randomized comparative studies, economic evaluations, qualitative studies and systematic reviews were selected purposively, appraised qualitatively for methodological limitations, and synthesized narratively by outcome, comparator, intervention comprehensiveness and directness of evidence for revascularized patients. Results: Compared with usual care, digital CR improved short-term exercise capacity; compared with center-based CR, it produced broadly similar exercise capacity and short- to intermediate-term quality of life. Lower odds of all-cause readmission with digital CR in one meta-analysis (OR 0.37, 95% CI 0.25–0.56) were based on only seven heterogeneous studies (n = 859) and are not corroborated by the 2023 Cochrane review; effects on major adverse cardiovascular events and mortality remain uncertain. Economic evaluations were generally favorable. Serious exercise-related adverse events were rarely reported in the selected, predominantly lower-risk participants studied, but surveillance was inconsistent, and safety after CABG and in higher-risk patients has not been established. Reimbursement, workforce capacity, interoperability and digital exclusion were the main implementation barriers. Conclusions: Comprehensive remote or hybrid CR is a reasonable option for appropriately assessed, clinically stable, lower-risk patients, particularly after PCI, and a promising way to reach those who would otherwise receive no rehabilitation; patients in the early period after CABG or at higher risk should start with supervised center-based or hybrid care. Digital CR should widen access to multidisciplinary rehabilitation rather than replace supervised programs, and adequately powered trials with long-term clinical and standardized safety outcomes are needed.
- Open Access
Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial
Background: COVID and Influenza with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs. Methods: A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 33 patients (53.2%) with BMI 28.14±0.39 kg/m 2 , and 29 patients without overweight with BMI 23.37 ± 0.38 kg/m 2 . T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan. Results: The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m 2 , and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m 2 (−9.7±0.7 kg vs. - 6.4±0.6 kg, respectively; P P P 96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3±1.31/101.6±0.85 vs. 118.3±0.46/80.89±0.66, P 9 /L) at 14-day of treatment (238.5±5.8, ×10 9 /L) ( P 9 /L) ( P P P <0.0001). The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment. Conclusions: The fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH. Trial Registration: ClinicalTrials.gov NCT05635539 . Registered 1 December 2022.
Open AccessWeight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial
Background: COVID and Influenza with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs. Methods: A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 33 patients (53.2%) with BMI 28.14±0.39 kg/m 2 , and 29 patients without overweight with BMI 23.37 ± 0.38 kg/m 2 . T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan. Results: The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m 2 , and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m 2 (−9.7±0.7 kg vs. - 6.4±0.6 kg, respectively; P P P 96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3±1.31/101.6±0.85 vs. 118.3±0.46/80.89±0.66, P 9 /L) at 14-day of treatment (238.5±5.8, ×10 9 /L) ( P 9 /L) ( P P P <0.0001). The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment. Conclusions: The fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH. Trial Registration: ClinicalTrials.gov NCT05635539 . Registered 1 December 2022.